- The report contains detailed information about Takeda Pharmaceutical Co. Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Takeda Pharmaceutical Co. Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Takeda Pharmaceutical Co. Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Takeda Pharmaceutical Co. Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Takeda Pharmaceutical Co. Ltd. business.
About Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The companys drugs are marketed in approximately 90 countries worldwide.
The company has an international marketing network, including Japan and 13 overseas bases in the U.S., Europe, and Asia. From these bases, the company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos).
The company operates its business in two categories, Pharmaceutical business and Other businesses.
The Pharmaceutical business represents the ethical drug business and healthcare business.
Other businesses include business activities involving the production and marketing of a range of products, including vitamin bulks, test reagents & clinical diagnostics, photographic chemicals, and inorganic chemicals.
Candesartan cilexetil is an angiotensin receptor blocker (ARB) that is used in hypertension treatment. Its once-daily dosing provides patients with a mild anti-hypertensive action. In addition, candesartan cilexetil is also applied for the treatment of chronic heart failure.
Once-daily dosing with pioglitazone hydrochloride improves insulin sensitivity and reduces blood glucose levels, without placing any additional burdens on the pancreas. The drug is marketed in approximately 80 countries worldwide. In the United States, Actoplus Met, a fixed-dose combination tablet of pioglitazone hydrochloride and metformin, as well as Duetact, a fixed-dose combination tablet of pioglitazone hydrochloride and glimepiride, are also marketed.
The company, in September 2007, entered into partnership with H. Lundbeck A/S for the development and commercialization of Lundbeck's portfolio of compounds, Lu AA21004, for the treatment of mood and anxiety disorders and entering Phase III studies in December 2007. This belongs to a new chemical class, with an active mechanism that differs from antidepressants.
In November 2009, Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity.
In January 2009, Seattle Genetics Inc. and Takeda Oncology with its parent company Takeda Pharmaceutical Co. Ltd. entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).
Takeda Pharmaceutical Company Limited was founded in 1781.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. TAKEDA PHARMACEUTICAL CO. LTD. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. TAKEDA PHARMACEUTICAL CO. LTD. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. TAKEDA PHARMACEUTICAL CO. LTD. SWOT ANALYSIS
4. TAKEDA PHARMACEUTICAL CO. LTD. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. TAKEDA PHARMACEUTICAL CO. LTD. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Takeda Pharmaceutical Co. Ltd. Direct Competitors
5.2. Comparison of Takeda Pharmaceutical Co. Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Takeda Pharmaceutical Co. Ltd. and Direct Competitors Stock Charts
5.4. Takeda Pharmaceutical Co. Ltd. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Takeda Pharmaceutical Co. Ltd. Industry Position Analysis
6. TAKEDA PHARMACEUTICAL CO. LTD. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. TAKEDA PHARMACEUTICAL CO. LTD. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. TAKEDA PHARMACEUTICAL CO. LTD. ENHANCED SWOT ANALYSIS2
9. JAPAN PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. TAKEDA PHARMACEUTICAL CO. LTD. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. TAKEDA PHARMACEUTICAL CO. LTD. PORTER FIVE FORCES ANALYSIS2
12. TAKEDA PHARMACEUTICAL CO. LTD. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Takeda Pharmaceutical Co. Ltd. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Takeda Pharmaceutical Co. Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Takeda Pharmaceutical Co. Ltd. Major Shareholders
Takeda Pharmaceutical Co. Ltd. History
Takeda Pharmaceutical Co. Ltd. Products
Revenues by Segment
Revenues by Region
Takeda Pharmaceutical Co. Ltd. Offices and Representations
Takeda Pharmaceutical Co. Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Takeda Pharmaceutical Co. Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Takeda Pharmaceutical Co. Ltd. Capital Market Snapshot
Takeda Pharmaceutical Co. Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Takeda Pharmaceutical Co. Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Takeda Pharmaceutical Co. Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Takeda Pharmaceutical Co. Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Takeda Pharmaceutical Co. Ltd. 1-year Stock Charts
Takeda Pharmaceutical Co. Ltd. 5-year Stock Charts
Takeda Pharmaceutical Co. Ltd. vs. Main Indexes 1-year Stock Chart
Takeda Pharmaceutical Co. Ltd. vs. Direct Competitors 1-year Stock Charts
Takeda Pharmaceutical Co. Ltd. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?